Glenmark Pharmaceuticals ltd — Capital/Financing Update 2022

Dec 14, 2022

==> picture [16 x 10] intentionally omitted <==

==> picture [17 x 10] intentionally omitted <==

==> picture [140 x 42] intentionally omitted <==

December 14, 2022

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001.

To, The Manager – Listing, The National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals Ltd. to divest its Cardiac brand, Razel®, in India and Nepal to J.B. Chemicals & Pharmaceuticals Limited

With reference to the subject mentioned above, kindly find attached notification which is self‐explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYA VINAYAK KUBER Date: 2022.12.14 K KUBER 16:26:50 +05'30'

Harish Kuber

Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [564 x 75] intentionally omitted <==

Exchange Notification

Subject: Glenmark Pharmaceuticals Ltd. to divest its Cardiac brand, Razel®, in India and Nepal to J.B. Chemicals & Pharmaceuticals Limited.

Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation‐driven, global pharmaceuticals company, today announced that it has entered into an agreement with J.B. Chemicals & Pharmaceuticals Limited to divest its cardiac brand, Razel (Rousvastatin and combinations), in India and Nepal for a consideration amount of INR 313.7 Cr. Razel and its combinations are indicated for the management of dyslipidemia. The transaction is expected to be closed by the end of this calendar year, subject to customary closing formalities.

This divestment is in line with Glenmark’s strategy of focusing on other sub‐categories of the cardio‐vascular segment. Going forward, the company will continue to further consolidate its position in its core therapeutic areas of cardio‐metabolic, respiratory, dermatology, and oncology.

‐‐‐End‐‐‐

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation‐driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world‐class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off‐patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com, LinkedIn (Glenmark Pharmaceuticals), Instagram (glenmark_pharma).

==> picture [558 x 28] intentionally omitted <==